Superworth

Phathom Pharmaceuticals price to sales ratio PHAT

Market value divided by revenue over the last twelve months, since 2024.

Today, Oct 23, 2026
1.9×
Peer median
1.5×

Phathom Pharmaceuticals' price to sales ratio is 1.9× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.9×1.9×7.6×
20258.5×2.4×20.1×
202421.3×19.4×43.9×

Against its peers

Companies in Drug Manufacturers - General nearest Phathom Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
PHATPhathom Pharmaceuticals1.9×
ARVNArvinas1.5×
PBYIPuma Biotechnology2.5×
IRWDIronwood Pharmaceuticals1.5×
ZVRAZevra Therapeutics4.3×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical0.9×
ABUSArbutus Biopharma4.6×
NATRNatures Sunshine Products0.4×
AMPHAmphastar Pharmaceuticals1.5×
OMEROmerosn/m
Peer median1.5×

Where Phathom Pharmaceuticals ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Phathom Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.